A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
Anixa Biosciences Inc
ANIX
$119M
Mkt Cap
$3.70
-1.33%
Anixa Biosciences Inc (ANIX) has a current P/E ratio of 11.6, compared to its historical median P/E of 9.5. The stock is currently considered Expensive based on its historical valuation range.
Anixa Biosciences Inc (ANIX) has a 5-year average return on invested capital (ROIC) of -52.0%. This is below average and may indicate limited pricing power.
Anixa Biosciences Inc (ANIX) has a market capitalization of $124M. It is classified as a small-cap stock.
Anixa Biosciences Inc (ANIX) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 0.00%.
Based on historical P/E analysis, Anixa Biosciences Inc (ANIX) appears expensive. The current P/E of 11.6 is 22% above its historical median of 9.5. The estimated fair value CAGR (P/E method) is 59.8%.
Anixa Biosciences Inc (ANIX) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Anixa Biosciences Inc (ANIX) generated $-7 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Item 1. Business Anixa Biosciences, Inc. is a biotechnology company developing therapies and vaccines that are focused on critical unmet needs in oncology. Our therapeutics program consists of the development of liraltagene autoleucel (“lira-cel”), a chimeric endocrine receptor-T cell therapy, which is a novel form of chimeric antigen receptor-T cell (“CAR-T”) technology, initially focused on treating ovarian cancer, that is being developed at our subsidiary, Certainty Therapeutics, Inc. (“Certainty”). Our vaccine programs include (i) the development of a vaccine against breast cancer, (ii) the development of a vaccine against ovarian cancer, and (iii) a vaccine discovery program utilizing the same mechanism as our breast and ovarian cancer vaccines to develop additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon and prostate. Our subsidiary, Certainty, is developing immuno-therapy drugs against cancer.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | - | - | - | - |
| Net Income | -10M | -13M | -9.8M | -14M | -13M | -10M |
| EPS | $-83.27 | $-0.39 | $-0.32 | $0.45 | $-0.45 | $-0.45 |
| Free Cash Flow | 0 | -7.3M | -6.2M | -6.5M | -4.9M | -6.2M |
| ROIC | -995.9% | -56.6% | -36.8% | -46.8% | -36.2% | -83.4% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.01 | 0.01 | 0.01 | - | 0.01 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -11M | -14M | -11M | -14M | -13M | -10.0M |
| Operating Margin | 0.0% | - | - | - | - | - |
| ROE | -68.4% | -56.6% | -36.8% | -46.8% | - | -114.3% |
| Shares Outstanding | 33M | 32M | 31M | 32M | 29M | 22M |
| Metric | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Revenue | N/A | N/A | 9.3M | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0 |
| Gross Margin | N/A | N/A | 62.1% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | N/A | N/A | 711K | 1.6M | 1.6M | 6.8M | 5.5M | 4.4M | 6.2M | 6.7M | 4.8M | 6.4M | 4.6M |
| SG&A | 8.0M | 6.4M | 5.5M | 2.7M | 4.4M | 6.9M | 5.7M | 5.6M | 7.1M | 7.2M | 6.3M | 7.4M | 6.4M |
| EBIT | -7.9M | -5.0M | -945K | -4.5M | -6.1M | -14M | -12M | -10.0M | -13M | -14M | -11M | -14M | -11M |
| Op. Margin | N/A | N/A | -10.2% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Net Income | -10M | -9.6M | N/A | -5.0M | -7.0M | -14M | -12M | -10M | -13M | -14M | -9.8M | -13M | -10M |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | -11K | 0 | -46K | 583K | 419K | 271K | 6K | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||||||||||
| ROIC | -115.0% | N/M | N/A | -63.3% | 97.6% | N/M | -179.4% | -83.4% | -36.2% | -46.8% | -36.8% | -56.6% | N/M |
| ROE | 446.6% | -239.6% | N/A | -166.1% | -157.5% | -209.6% | -218.3% | -114.3% | N/A | -46.8% | -36.8% | -56.6% | -68.4% |
| ROA | -181.6% | -132.5% | N/A | -67.0% | -97.2% | -183.4% | -182.8% | -106.0% | -56.7% | -44.7% | -35.1% | -53.3% | -67.7% |
| Cash Flow | |||||||||||||
| Op. Cash Flow | -3.2M | -2.4M | 1.4M | -3.4M | -3.8M | -4.3M | -4.7M | -6.2M | -4.9M | -6.5M | -6.2M | -7.3M | -6.9M |
| Free Cash Flow | -3.2M | -2.4M | 1.3M | -3.5M | -3.8M | -4.3M | -4.9M | -6.2M | -4.9M | -6.5M | -6.2M | -7.3M | 0 |
| Owner Earnings | -5.9M | -4.8M | -1.3M | -4.3M | -5.1M | -10M | -8.4M | -10M | -12M | -13M | -11M | -12M | -10M |
| CapEx | 0 | 7K | 55K | 147K | 30K | 38K | 175K | 16K | 0 | 16K | 0 | 0 | 0 |
| Maint. CapEx | 46K | 314K | 14K | 47K | 36K | 54K | 95K | 38K | 0 | 38K | 0 | 0 | 0 |
| Growth CapEx | N/A | 0 | 41K | 100K | 0 | 0 | 80K | 0 | N/A | 0 | N/A | N/A | 0 |
| D&A | 46K | 314K | 14K | 47K | 36K | 54K | 95K | 38K | 0 | 38K | 0 | 0 | 0 |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 4.1M | 445K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6K | 6K |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | N/A | 0.0% | 0.0% |
| Stock-Based Comp | 2.7M | 2.1M | 2.7M | 874K | 1.2M | 5.7M | 3.6M | 3.9M | 7.5M | 6.0M | 4.4M | 4.4M | 3.4M |
| Debt Repayment | 0 | 200K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||||||||||
| Net Debt | -350K | -3.4M | -6.0M | -2.8M | N/A | N/A | N/A | -9.0M | -35M | -29M | -24M | -20M | -14M |
| Cash & Equiv. | 898K | 3.4M | 4.4M | 2.5M | 3.3M | 3.1M | 3.5M | 6.4M | 29M | 12M | 915K | 1.3M | 14M |
| Long-Term Debt | 549K | N/A | 370K | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt/Equity | -0.17 | 0.61 | 0.15 | 0.47 | 0.11 | 0.23 | 0.28 | 0.01 | N/A | 0.01 | 0.01 | 0.01 | 0.00 |
| Interest Coverage | -7.1 | -4.0 | -2.1 | -8.7 | -12.1 | N/A | -213.4 | -250.1 | -6568.0 | N/A | N/A | N/A | N/A |
| Equity | -3.3M | 4.0M | 5.1M | 987K | 7.9M | 5.4M | 5.2M | 8.8M | N/A | 29M | 24M | 20M | 15M |
| Total Assets | 5.4M | 9.1M | 9.3M | 5.6M | 8.8M | 6.4M | 6.3M | 9.5M | 36M | 30M | 26M | 22M | 15M |
| Total Liabilities | 8.8M | 5.0M | 4.3M | 4.6M | 889K | 1.3M | 1.5M | 1.2M | N/A | 2.2M | 2.2M | 2.7M | 1.4M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -135M | -145M | -146M | -151M | -156M | -170M | -182M | -192M | -205M | -218M | -228M | -241M | -254M |
| Working Capital | -2.0M | 4.5M | 6.3M | 2.9M | 6.1M | 4.3M | 4.6M | 8.2M | 35M | 28M | 23M | 19M | 14M |
| Current Assets | 1.2M | 6.3M | 6.9M | 3.4M | 7.0M | 5.5M | 6.1M | 9.4M | 36M | 30M | 25M | 21M | 15M |
| Current Liabilities | 3.2M | 1.8M | 594K | 469K | 889K | 1.3M | 1.5M | 1.2M | 1.3M | 2.0M | 2.0M | 2.5M | 1.2M |
| Per Share Data | |||||||||||||
| EPS | -0.63 | -13.75 | -8.00 | -0.29 | -0.58 | -0.79 | -0.59 | -0.45 | -0.45 | 0.45 | -0.32 | -0.39 | -83.27 |
| Owner EPS | -0.37 | -6.90 | N/A | -0.24 | -0.42 | -0.57 | -0.43 | -0.46 | -0.43 | -0.40 | -0.35 | -0.37 | -0.31 |
| Book Value | -0.21 | 5.74 | N/A | 0.06 | 0.65 | 0.31 | 0.27 | 0.39 | N/A | 0.92 | 0.79 | 0.62 | 0.45 |
| Cash Flow/Share | -0.20 | -3.41 | N/A | -0.19 | -0.31 | -0.24 | -0.24 | -0.28 | -0.17 | -0.20 | -0.20 | -0.23 | -0.31 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 16.1M | 0.7M | N/A | 17.6M | 12.1M | 17.7M | 19.7M | 22.3M | 28.8M | 31.7M | 30.7M | 32.2M | 33.5M |
| Valuation | |||||||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 9.5 | N/A | -0.0 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 4.1 | N/A | 8.2 |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| FCF Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -6.4% | N/A | N/A |
| Market Cap | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 96M | 0 | 124M |
| Avg. Price | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.00 | 0.00 | 3.70 |
| Year-End Price | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.04 | 0.00 | 3.70 |
Anixa Biosciences Inc passes 1 of 9 quality checks, indicating weak fundamentals.
Anixa Biosciences Inc trades at 11.6x trailing earnings, compared to its 15-year median P/E of 9.5x, suggesting it is currently Expensive relative to its historical range. At current prices, the estimated annualized return to fair value is +59.8%.
Anixa Biosciences Inc (ANIX) has a debt-to-equity ratio of 0.01. This indicates a conservatively financed balance sheet.
Anixa Biosciences Inc (ANIX) reported earnings per share (EPS) of $-0.39 in its most recent fiscal year.
Anixa Biosciences Inc (ANIX) has a return on equity (ROE) of -56.6%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 15 years of financial data for Anixa Biosciences Inc (ANIX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Anixa Biosciences Inc (ANIX) has a book value per share of $0.62, based on its most recent annual SEC filing.